Loading
A phase 1/2 trial of Sonrotoclax and Azacitidine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by BeOne Medicines, now recruiting.
A Study of BGB-11417 in Participants With Myeloid Malignancies is a phase 1/2 interventional study registered as NCT04771130 by BeOne Medicines, with 260 participants planned, started 2021-05-24 and due to reach its primary completion in 2028-08-31. Interventions recorded: BGB-11417, Azacitidine and Posaconazole.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares Sonrotoclax, BCL-2 inhibitors, BeOne Medicines (formerly BeiGene), Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Azacitidine, Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/